Open AccessLong-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function
Author(s) -
Katia Khoury,
Filipa Lynce,
Ana Barac,
Xue Geng,
Chau T. Dang,
Anthony F. Yu,
Karen L. Smith,
Christopher Gallagher,
Paula R. Pohlmann,
Raquel Nunes,
Pia Herbolsheimer,
Robert Warren,
Monvadi B. Srichai,
Mark Hofmeyer,
Federico M. Asch,
Ming Tan,
Claudine Isaacs,
Sandra M. Swain
Publication year - 2021
Publication title -
breast cancer research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.908
H-Index - 154
eISSN - 1573-7217
pISSN - 0167-6806
DOI - 10.1007/s10549-020-06053-y
Subject(s) - medicine , ejection fraction , breast cancer , trastuzumab , heart failure , cardiotoxicity , pertuzumab , clinical endpoint , asymptomatic , metastatic breast cancer , cancer , targeted therapy , cardiac function curve , cardiology , oncology , clinical trial , surgery , chemotherapy
HER2-targeted therapies are associated with cardiotoxicity which is usually asymptomatic and reversible. We report the updated cardiac safety assessment of patients with compromised heart function receiving HER2-targeted therapy for breast cancer, enrolled in the SAFE-HEaRt trial, at a median follow-up of 3.5 years.